A new trial (UMIN000027873) has been recently launched to evaluate the therapeutic effect of nivolumamb as a second-line therapy for advanced CCRCC based on the concentrations of serum sPD-L1. Here, SPDL1 is linked to nonpapillary renal cell carcinoma.